Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, genetic disease, caused by lack of lysyl hydrohylase 3 (LH3) activity, characterized by multiple tissue and organ involvement, including skeletal abnormalities (club foot, progressive scoliosis, osteopenia, pathologic fractures), ocular involvement (flat retinae, myopia, cataracts) and hair, nail and skin anomalies (coarse, abnormally distributed hair, skin blistering, reduced palmar creases, hypoplastic nails). Patients also present intrauterine growth retardation, facial dysmorphism (flat facial profile, low-set ears, shallow orbits, short and upturned nose, downturned corners of mouth) and joint flexion contractures. Growth and developmental delay, bilateral sensorineural deafness, friable diaphragm and later-onset spontaneous vascular ruptures are additional reported features.
Features include always present findings: Anteverted nares, Nail dysplasia, Short nose, and J-shaped sella turcica and others; and common findings: Enlarged brain ventricles (ventriculomegaly), Porencephalic cyst, Overlapping fingers, and Pointed chin. 39 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 6 | Hypoplasia of the capital femoral epiphysis, Contracture of the proximal interphalangeal joint of the 2nd finger, Mild bone density loss (osteopenia) |
PLOD3 function has not been fully characterized.
Bone fragility with contractures, arterial rupture, and deafness is associated with mutations in the PLOD3 gene on chromosome 7.
Genetic testing for PLOD3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for bone fragility with contractures, arterial rupture, and deafness has been reported in the published literature.
Phenotype severity distribution: 31 always present features, 4 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for bone fragility with contractures, arterial rupture, and deafness.
109 publications have been identified in PubMed for bone fragility with contractures, arterial rupture, and deafness. Research spans Review / Meta-Analysis (54%), Basic Science / Preclinical (15%), and Case Report / Case Series (11%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 59 | 54% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 11:22 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Muscles | 4 | Thenar muscle atrophy, Contracture of the proximal interphalangeal joint of the 2nd finger, Contracture of the proximal interphalangeal joint of the 3rd finger |
Arms and legs | 3 | Contracture of the proximal interphalangeal joint of the 2nd finger, Overlapping fingers, Contracture of the proximal interphalangeal joint of the 3rd finger |
Brain and nerves | 3 | Enlarged brain ventricles (ventriculomegaly), Global developmental delay, Dilatation of the cerebral artery |
Growth and development | 2 | Postnatal growth retardation, Intrauterine growth retardation |
Skin | 1 | Nail dysplasia |
Head and neck | 1 | Flat face |
Eyes | 1 | Cataract |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
Blood and immune system | 1 | Low platelet count (thrombocytopenia) |
Laboratory research |
16 |
15% |
Patient case studies | 12 | 11% |
Disease patterns and progression | 10 | 9% |
Clinical study results | 4 | 4% |
New treatment approaches | 4 | 4% |
Other research | 2 | 2% |
Testing and diagnosis research | 2 | 2% |
Zhytnik L (2026). [PMID: 41051363](https://pubmed.ncbi.nlm.nih.gov/41051363/). *J Bone Miner Res*. [Basic Science / Preclinical]
Howard MC (2026). [PMID: 41774788](https://pubmed.ncbi.nlm.nih.gov/41774788/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Kim D (2026). [PMID: 41326232](https://pubmed.ncbi.nlm.nih.gov/41326232/). *AJNR Am J Neuroradiol*. [Review / Meta-Analysis]
Choudhary D (2026). [PMID: 41827019](https://pubmed.ncbi.nlm.nih.gov/41827019/). *Genome Med*. [Gene Therapy / Novel Therapeutics]
Peramato Martín E (2026). [PMID: 41666512](https://pubmed.ncbi.nlm.nih.gov/41666512/). *Semergen*. [Review / Meta-Analysis]
Minisola S (2026). [PMID: 41092268](https://pubmed.ncbi.nlm.nih.gov/41092268/). *J Bone Miner Res*. [Review / Meta-Analysis]
Feng S (2026). [PMID: 41231548](https://pubmed.ncbi.nlm.nih.gov/41231548/). *JCI Insight*. [Basic Science / Preclinical]
Alperovich M (2025). [PMID: 40210850](https://pubmed.ncbi.nlm.nih.gov/40210850/). *Nat Rev Dis Primers*. [Review / Meta-Analysis]
Sahoo SS (2025). [PMID: 39475954](https://pubmed.ncbi.nlm.nih.gov/39475954/). *Blood*. [Review / Meta-Analysis]
Zoref-Lorenz A (2025). [PMID: 39656557](https://pubmed.ncbi.nlm.nih.gov/39656557/). *Leuk Lymphoma*. [Review / Meta-Analysis]